TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34982798

Group type: EXPERIMENTAL
Intervention: HBV Enh‐II region mutations in HCC patients
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: HBV Enh‐II region mutations in LC patients
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: HBV Enh‐II region mutations in CH patients
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: H94 deletion in the Enh‐II region
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Notable mutations E109A/Y, A110S/K, Y111D/E, F112L
Number of subjects: 200
Study: 34376486

Group type: EXPERIMENTAL
Intervention: Serum bile acids
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Fecal bile acids
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Serum short chain fatty acids
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Fecal short chain fatty acids
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Bile acids and short chain fatty acids
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Bile acids
Number of subjects: 136
Study: 35427929

Group type: EXPERIMENTAL
Intervention: Dual-task group (DT) with an additional auditory 1-back task
Number of subjects: 80

Group type: COMPARATOR
Intervention: Single task group (ST)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dual-task group with visual feedback delay (DTDEL)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Single task group with visual feedback delay (STDEL)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Dual-task group without visual feedback delay (DTNoDEL)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Single task group without visual feedback delay (STNoDEL)
Number of subjects: 80
Study: 32772079

Group type: EXPERIMENTAL
Intervention: NNRTI-based ART
Number of subjects: 170
Study: 35771552

Group type: EXPERIMENTAL
Intervention: CHW-led intervention (usual care with 6-month CHW-led intervention)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: CHW-led intervention
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 128
Study: 34204042

Group type: EXPERIMENTAL
Intervention: Natural extract of Sclerocarya birrea, 100 mg daily for 90 days
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 35451391

Group type: EXPERIMENTAL
Intervention: 0.2 μg/(kg·h) of dexmedetomidine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.3 μg/(kg·h) of dexmedetomidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.4 μg/(kg·h) of dexmedetomidine
Number of subjects: 60
Study: 35917052

Group type: EXPERIMENTAL
Intervention: Neoadjuvant endocrine therapy (NET) for 4 months before surgery
Number of subjects: 410

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy
Number of subjects: 410
Study: 35568822

Group type: EXPERIMENTAL
Intervention: Intratracheal dexmedetomidine (1 µg/kg) combined with 0.8% ropivacaine (40 mg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Normal saline (Control Group S)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Intratracheal dexmedetomidine (1 µg/kg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 0.8% ropivacaine (40 mg)
Number of subjects: 200
Study: 33546947

Group type: EXPERIMENTAL
Intervention: Highest quartile of netrin-1
Number of subjects: 3065

Group type: COMPARATOR
Intervention: Normal TC levels
Number of subjects: 3065

Group type: EXPERIMENTAL
Intervention: Netrin-1 added to conventional risk factors
Number of subjects: 3065
Study: 36469298

Group type: COMPARATOR
Intervention: Prednisolone 40 mg/day for 28 days
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) through naso-duodenal tube, daily for seven days
Number of subjects: 120
Study: 33169227

Group type: EXPERIMENTAL
Intervention: Resective epilepsy surgery
Number of subjects: 3

Group type: COMPARATOR
Intervention: Medically treated patients
Number of subjects: 3
Study: 32954415

Group type: EXPERIMENTAL
Intervention: Pharmacological therapy (specific drugs not mentioned) for VVS patients
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Bifascicular block patients
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Patients with ≥4 faints in the prior year
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Overall group of syncope patients
Number of subjects: 459
Study: 34285005

Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg once daily) + Exenatide QW (2 mg once weekly)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Dapagliflozin (10 mg once daily)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control (placebo tablet and sham injection)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Dapagliflozin + Exenatide QW
Number of subjects: 110
Study: 32135610

Group type: EXPERIMENTAL
Intervention: Type C lesion group (n=614)
Number of subjects: 1255

Group type: COMPARATOR
Intervention: Type A/B1 lesion group (n=184)
Number of subjects: 1255

Group type: COMPARATOR
Intervention: Type B2 lesion group (n=457)
Number of subjects: 1255
Study: 36050633

Group type: EXPERIMENTAL
Intervention: One-handed child chest compression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two-handed child chest compression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32958014

Group type: COMPARATOR
Intervention: nab-P 40 µmol/l
Number of subjects: 0

Group type: COMPARATOR
Intervention: AP 50 µmol/l
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: nab-P 5 µmol/l + AP 10 µmol/l
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: nab-P 20 mg/kg + AP 150 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: nab-P 18 mg/kg + AP 150 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: nab-P 16 mg/kg + AP 150 mg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduced doses of nab-P
Number of subjects: 0
Study: 35505441

Group type: EXPERIMENTAL
Intervention: 5‐mg/mL EGCG solution
Number of subjects: 15

Group type: COMPARATOR
Intervention: Routine periodontal therapy (Control)
Number of subjects: 15
Study: 33306989

Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV‐19 vaccine (two standard doses)
Number of subjects: 23648

Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV‐19 vaccine (low dose followed by standard dose)
Number of subjects: 23648

Group type: EXPERIMENTAL
Intervention: Overall efficacy of ChAdOx1 nCoV‐19 vaccine
Number of subjects: 23648

Group type: COMPARATOR
Intervention: Control group (meningococcal group A, C, W, and Y conjugate vaccine or saline)
Number of subjects: 23648

Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV‐19 vaccine and control group
Number of subjects: 23648
Study: 35877150

Group type: EXPERIMENTAL
Intervention: Heated humidified high-flow nasal cannula (HHHFNC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 30
Study: 33136088

Group type: EXPERIMENTAL
Intervention: Isolated trunk extensor (TE) muscle endurance
Number of subjects: 30
Study: 32967619

Group type: EXPERIMENTAL
Intervention: Educational intervention for general practitioners (GPs) aimed at initiating and optimizing advance care planning (ACP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Educational intervention for GPs
Number of subjects: 0
Study: 36237892

Group type: EXPERIMENTAL
Intervention: Web-based teaching material
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Paper-based teaching material
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 69
Study: 33780486

Group type: EXPERIMENTAL
Intervention: Digital early literacy intervention
Number of subjects: 695

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: Gold standard measures (various definitions)
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: Most precise definition of the gold standard level
Number of subjects: 695
Study: 32788190

Group type: EXPERIMENTAL
Intervention: HPV vaccine, Gardasil 9
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo hepatitis A vaccine, Avaxim
Number of subjects: 0
Study: 35906874

Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified balanced energy-protein (BEP) supplement and iron-folic acid (IFA) tablet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Iron-folic acid (IFA) tablet
Number of subjects: 0
Study: 33779698

Group type: EXPERIMENTAL
Intervention: Ponesimod (20 mg once daily)
Number of subjects: 1133

Group type: COMPARATOR
Intervention: Teriflunomide (14 mg once daily)
Number of subjects: 1133
Study: 32912597

Group type: EXPERIMENTAL
Intervention: Venlafaxine extended release (VEN)
Number of subjects: 2599

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2599

Group type: EXPERIMENTAL
Intervention: Venlafaxine extended release (VEN) lower-dose subgroup
Number of subjects: 2599

Group type: EXPERIMENTAL
Intervention: Venlafaxine extended release (VEN) higher-dose subgroup
Number of subjects: 2599
Study: 35325161

Group type: EXPERIMENTAL
Intervention: Intragastric quinine hydrochloride (600 mg QHCl)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Intraduodenal quinine hydrochloride (600 mg QHCl)
Number of subjects: 28
Study: 32452896

Group type: EXPERIMENTAL
Intervention: Real-time SYNTAX score feedback from image analysts during intervention period.
Number of subjects: 3245

Group type: COMPARATOR
Intervention: Control group with SYNTAX scores calculated by treating cardiologists.
Number of subjects: 3245
Study: 35162627

Group type: EXPERIMENTAL
Intervention: Balance combined with plyometric training (PB)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Plyometric training (PT)
Number of subjects: 16
Study: 33017565

Group type: EXPERIMENTAL
Intervention: Early Physical Therapy (EPT)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 220
Study: 32517123

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus ATCC 53103 for 28 days at a dosage of 5 × 10^9 cfu per day
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus ATCC 53103 for 28 days
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 33549445

Group type: EXPERIMENTAL
Intervention: Unsupervised Nordic walking (NW)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Unsupervised walking (W)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 27
Study: 32818946

Group type: EXPERIMENTAL
Intervention: Weight loss programme for 12 weeks
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Weight loss programme for 52 weeks
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Attendance group (10-12 sessions)
Number of subjects: 889

Group type: COMPARATOR
Intervention: Control group (brief support only)
Number of subjects: 889
Study: 35441218

Group type: EXPERIMENTAL
Intervention: Daily rice bran supplementation (1 to 5 g/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34721259

Group type: EXPERIMENTAL
Intervention: Robot-aided stretching device
Number of subjects: 20

Group type: COMPARATOR
Intervention: Manual stretching
Number of subjects: 20
Study: 32816895

Group type: EXPERIMENTAL
Intervention: Ipilimumab following CRT
Number of subjects: 26

Group type: COMPARATOR
Intervention: CRT only
Number of subjects: 26
Study: 34214479

Group type: EXPERIMENTAL
Intervention: Imatinib (400 mg, 4 × 100 mg film‐coated tablets per day for 26 weeks)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 67
Study: 32047963

Group type: EXPERIMENTAL
Intervention: IVRSS-PSP training
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional model (NON-VR group)
Number of subjects: 24
Study: 36152764

Group type: EXPERIMENTAL
Intervention: 25% IV albumin 1.5g/kg weekly infusions
Number of subjects: 48

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 48
Study: 33026700

Group type: EXPERIMENTAL
Intervention: Daratumumab added to lenalidomide and dexamethasone
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Daratumumab added to bortezomib, melphalan, and prednisone
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Daratumumab added to bortezomib, thalidomide, and dexamethasone
Number of subjects: 3

Group type: COMPARATOR
Intervention: Daratumumab (various combinations)
Number of subjects: 3
Study: 35712635

Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed cow’s milk protein formula (PHF, 75% carbohydrate as lactose; 12 mg Mg/100 kcal)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine intact protein cow’s milk‐based infant formula (Control, 92% carbohydrate as lactose; 8 mg Mg/100 kcal)
Number of subjects: 100
Study: 33470739

Group type: EXPERIMENTAL
Intervention: Dynamic Spectral Imaging (DSI) colposcopy
Number of subjects: 417

Group type: COMPARATOR
Intervention: Regular colposcopy
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Both DSI and regular colposcopy
Number of subjects: 417
Study: 34980410

Group type: EXPERIMENTAL
Intervention: Human safety claims (with 'Antibiotic‐free' and 'Pathogen‐ and zoonosis‐free')
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Animal welfare claims (with 'No animal breeding' and 'No animal slaughtering')
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Environmental impact claims (with '82‐96% reduction of water consumption' and '99% reduction of soil usage')
Number of subjects: 603

Group type: COMPARATOR
Intervention: No additional information (control)
Number of subjects: 603
Study: 32200425

Group type: EXPERIMENTAL
Intervention: Use of diagnostic algorithm
Number of subjects: 224

Group type: COMPARATOR
Intervention: No algorithm (control group)
Number of subjects: 224
Study: 36001840

Group type: EXPERIMENTAL
Intervention: Perioperative IV TA alone and post‐operative oral TA (n=26)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Perioperative IV TA plus 48 hours additional oral placebo (n=24)
Number of subjects: 50
Study: 34507703

Group type: EXPERIMENTAL
Intervention: LED phototherapy (630 nm and 940 nm) at a dose of 6 J/cm2, three times a week for 8 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: LED phototherapy (630 nm and 940 nm) at a dose of 8 J/cm2, three times a week for 8 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard treatment (control group) consisting of cleaning with physiological solution and alginate hydrogel dressing, daily for 8 weeks
Number of subjects: 15
Study: 33612595

Group type: EXPERIMENTAL
Intervention: High-protein polymeric formula
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (5% Dextrose)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Oligomeric formula
Number of subjects: 55
Study: 34580032

Group type: EXPERIMENTAL
Intervention: Active group (educational approach with 31 deprescribing-related clinical case scenarios delivered through WhatsApp)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Active group
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 108
Study: 35229945

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 308

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study: 33733965

Group type: EXPERIMENTAL
Intervention: 75% hypertonic glucose (HG)
Number of subjects: 159

Group type: COMPARATOR
Intervention: 0.2% sodium tetradecyl sulfate (STS)
Number of subjects: 159
Study: 32393498

Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine
Number of subjects: 404
Study: 35034949

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2 mA, for 20 min)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham stimulation (2 mA, for 30 s, ramped up, then ramped down)
Number of subjects: 30
Study: 33750471

Group type: COMPARATOR
Intervention: Biologic therapy targeting Type 2 inflammatory pathway (e.g., IL-4, IL-5, IL-13, IL-5R, IL-33, IgE)
Number of subjects: 0
Study: 32925776

Group type: EXPERIMENTAL
Intervention: Fascia iliaca compartment block (FICB) with 5mg/mL of epinephrine and 40 mL of ropivacaine 0.2%
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-FICB (placebo control)
Number of subjects: 100
Study: 35608567

Group type: EXPERIMENTAL
Intervention: Supervised resistance training
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Home-based resistance training
Number of subjects: 59

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 59
Study: 36040717

Group type: EXPERIMENTAL
Intervention: Self-expanding THV
Number of subjects: 1644

Group type: COMPARATOR
Intervention: Balloon-expandable THV
Number of subjects: 1644
Study: 36052812

Group type: EXPERIMENTAL
Intervention: PLEASED intervention (peer-led diabetes self-management support)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 196
Study: 33710814

Group type: COMPARATOR
Intervention: ondansetron/dexamethasone (D1)
Number of subjects: 304

Group type: COMPARATOR
Intervention: aprepitant/ondansetron/dexamethasone (D1-3)
Number of subjects: 304

Group type: COMPARATOR
Intervention: aprepitant/ondansetron/dexamethasone (D1-3) with olanzapine
Number of subjects: 304

Group type: COMPARATOR
Intervention: aprepitant/ondansetron/dexamethasone (D1)
Number of subjects: 304
Study: 32115470

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 35

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 35
Study: 34438361

Group type: EXPERIMENTAL
Intervention: 14 mg saffron extract (affron®)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 28 mg saffron extract (affron®)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Saffron supplementation
Number of subjects: 120
Study: 32155616

Group type: EXPERIMENTAL
Intervention: Basil essential oil 2%, 4%, 6%
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 36435760

Group type: EXPERIMENTAL
Intervention: iAssist system (hand-held navigation)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional instruments
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: iAssist system
Number of subjects: 60
Study: 34460973

Group type: EXPERIMENTAL
Intervention: Pregabalin (75 mg daily)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 34357880

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Platelet-Poor Plasma (PPP)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: PRP irrigation
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: PRP injection
Number of subjects: 500
Study: 32472928

Group type: EXPERIMENTAL
Intervention: High-heat capacity mattress (MAT)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy (WBC)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: High-speed running distance
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Supplementary collisions
Number of subjects: 19
Study: 34259904

Group type: EXPERIMENTAL
Intervention: Theophylline as an add-on to thrombolytic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo as an add-on to thrombolytic therapy
Number of subjects: 0
Study: 33407269

Group type: EXPERIMENTAL
Intervention: 0.4 ml/kg Formulaid™ (100 mg/kg of ARA and 50 mg/kg of DHA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: 0.4 ml/kg MCT‐oil™ (medium chain triglycerides)
Number of subjects: 120
Study: 35852528

Group type: EXPERIMENTAL
Intervention: 4% albumin solution
Number of subjects: 1407

Group type: COMPARATOR
Intervention: Ringer acetate solution
Number of subjects: 1407
Study: 34444817

Group type: EXPERIMENTAL
Intervention: 200 mg of CoQ10 and 20 mg of NADH once daily
Number of subjects: 207

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 207
Study: 32653082

Group type: EXPERIMENTAL
Intervention: Brainwave entrainment
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study: 35034630

Group type: EXPERIMENTAL
Intervention: Video-assisted pulmonary metastasectomy
Number of subjects: 512

Group type: COMPARATOR
Intervention: Thoracotomy
Number of subjects: 512
Study: 33728845

Group type: EXPERIMENTAL
Intervention: Psychiatric rehabilitation along with standard pharmacological treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard pharmacological treatment alone
Number of subjects: 100
Study: 35312182

Group type: EXPERIMENTAL
Intervention: GPR (gamma-glutamyl transpeptidase-to-platelet ratio) with a cutoff of <0.35
Number of subjects: 880

Group type: COMPARATOR
Intervention: APRI (aspartate aminotransferase-to-platelet ratio index)
Number of subjects: 880

Group type: COMPARATOR
Intervention: FIB-4 (fibrosis-4 scoring system)
Number of subjects: 880
Study: 34886576

Group type: EXPERIMENTAL
Intervention: Yelling intervention during Coriolis stimulation (5-8 times yelling)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control trial (keeping quiet during each minute of rotation)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Yelling intervention during Coriolis stimulation
Number of subjects: 42
Study: 33180150

Group type: EXPERIMENTAL
Intervention: ECLS (Extracorporeal Life Support)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (no ECLS)
Number of subjects: 42
Study: 32412900

Group type: EXPERIMENTAL
Intervention: Bifidobacterium triple viable capsule therapy
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Low-fat dietary intervention
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combination of low-fat diet and Bifidobacterium triple viable capsule therapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 36
Study: 35041159

Group type: EXPERIMENTAL
Intervention: Galcanezumab 120 mg/month (240 mg loading dose)
Number of subjects: 462

Group type: EXPERIMENTAL
Intervention: Galcanezumab
Number of subjects: 462

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 462
Study: 33504485

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 1755

Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg
Number of subjects: 1755

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1755

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg biweekly
Number of subjects: 1755
Study: 32882036

Group type: EXPERIMENTAL
Intervention: Oral octreotide capsules (OOCs)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56